Searched for
LUPIN PART 4
Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...- Lupin season 4 release date on Netflix: Is Lupin part 4 happening?Lupin season 4 will be releasing on Netflix even though the production for the same is yet to commence, according to a report.
- Lupin shares drop 3% after Q3 resultsShares of Lupin Ltd dropped 2.8% despite a significant Q3 profit increase of 38.8% year-on-year. The company's revenue surged 102.7%, reach...
- Netflix movies, series: Most watched English, non-English films, shows of streaming giantNetflix's most watched movies and series in the English and non-English categories have been unveiled.
- 5 stocks and the making of the legend of Big BullLupin is the other favourite stock pick of Jhunjhunwala that made him some big money. He started buying Lupin shares in 2003 when the marke...
- Neutral on Lupin, target price Rs 1320: Motilal OswalLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 54257.88 Crore) operating in Pharmaceuticals s...
- Buy Lupin, target price Rs 1165: ICICI DirectLupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 47082.92 Crore) operating in Pharmaceuticals s...
- Exploring ways to establish presence in China as part of APAC region push: LupinThe Mumbai-based firm expects to generate revenues of over USD 100 million from the region, excluding the Japanese market, over the next fe...
- Lupin reports Rs 777 crore Q4 loss on one-time impairment provisionsThe company had reported Rs 707 crore profit for the year-ago quarter.
- Lupin founder DB Gupta, a self made maverick who wanted to take out TB in India, deadGupta is survived by wife and five children (four daughters and a son) Vinita Gupta, the eldest daughter and Nilesh Gupta were handed over ...
- Lupin to market Novartis' inhaler under Loftair brand nameAccording to IMS sales data, Lupin is ranked second with 12.4 per cent market share of the overall anti-asthma segment within the Indian ph...
- Day 1 on Sensex: Lupin erases early gains on profit-bookingAfter rising 1.91 % to Rs 1,851.15 in intra-day trade, shares of Lupin succumbed to profit-booking and finally ended at Rs 1,811.10.
- Lupin becomes part of Sensex; ends in redThe stock gained 1.91 per cent to Rs 1,851.15 at BSE. On NSE, it climbed 1.86 per cent to Rs 1,850.75.
- Lupin likely to sign $1.5 billion deal with Merck SeronoLupin will manufacture Merck Serono’s $1.5 billion worth branded mature drugs at its facilities. The company will also get marketing rights...
- Lupin expects to launch 20 products in US next fiscalDrug major Lupin expects to strengthen its US pipeline by launching around 20 products in the next fiscal (2014-15).
- Japan's Takeda eyes Lupin, Cipla pharma business; shares surge in morning tradeShares of drug firms Cipla and Lupin surged after news reports surfaced that Takeda Pharmaceutical Co, is in talks to buy either of their p...
- Japan's Takeda eyes Lupin, Cipla pharma businessTakeda, Japan's largest pharmaceutical firm, has begun talks with two of India's biggest companies for purchasing either of their pharma bu...
- Lupin aims to break into top 5 in Japanese marketDrug maker Lupin today said it is aiming to become one of the top five generic pharmaceutical companies in Japan in the next three years.
- Lupin to launch more branded generics in USLupin Pharma will launch a new branded generic drug in the US every year for specialised therapeutic areas.
- Lupin sends notice to Oscient over cholesterol genericIndian pharma major Lupin has sent a legal notice to US-based Oscient Pharmaceuticals to inform them that they are seeking regulatory appro...
Load More
